Bais C, Mueller B, Brady MF, Mannel RS, Burger RA, Wei W, Marien KM, Kockx MM, Husain A, Birrer MJ: Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses. J Natl Cancer Inst 109 (11): 2017.
Shalowitz DI, Nivasch E, Burger RA, Schapira MM: Are Patients Willing to Travel for Better Ovarian Cancer Care? Gynecol Oncol In Press : 2017.
Phippen NT, Secord AA, Wolf S, Samsa G, Davidson B, Abernethy AP, Cella D, Havrilevsky LJ, Burger RA, Monk BJ: Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: an ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study Gynecol Oncol 147 (1): 2017.
Oliver KE, Brady WE, Birrer MJ, Gershenson DM, Fleming G, Copeland LJ, Tewari K, Argenta PA, Mannel RS, Alvarez-Secord A, Stephan J-M, Mutch DG, Stehman FB, Muggia FM, Rose PG, Armstrong DK, Bookman MA, Burger RA.: An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience. Gynecol Oncol In Press : 2017.
Cory L, Latif N, Brensinger C, Zhang X, Giuntoli RL 2nd, Burger RA, Morgan M, Ko E.: Readmission After Gynecologic Surgery: A Comparison of Procedures for Benign and Malignant Indications. Obstet Gynecol 130 (2): 285-295,2017.
Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, DiSaia PJ, Copeland LJ, Creasman WT, Stehman FB, Brady MF, Burger RA, Thigpen JT, Birrer MJ, Waggoner SE, Moore DH, Look KY, Koh WJ, Monk BJ: Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240) Lancet In Press : 2017.
Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, DiSaia PJ, Copeland LJ, Creasman WT, Stehman FB, Brady MF, Burger RA, Thigpen JT, Birrer MJ, Waggoner SE, Moore DH, Look KY, Koh W-J, Monk BJ: Bevacizumab for advanced cervical cancer: final overall
survival and adverse event analysis of a randomised,
controlled, open-label, phase 3 trial (Gynecologic Oncology
Group 240) The Lancet In Press : 2017.
Karam A, Ledermann JA, Kim JW, Sehouli J, Gourley C, Katsumata N, Burger RA, Nam BH, Bacon M, Ng C, Pfisterer J, Bekkers RL, Casado-Herraez A, Redondo A, Fujiwara H, Gleeson N, Rosengarten O, Scambia G, Zhu J, Okamoto A, Stuart G, Ochiai K.: Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions. Ann Oncol 28 (4): 711-7,2017.
Buckingham L, Haggerty AF, Zhang X, Burger RA, Morgan MA, Ko EM, Andy UU, Giuntoli RL.: Sexual function following hysterectomy for endometrial cancer: A five-year follow-up investigation. Poster presentation at the 2017 Annual Meeting on Women's Cancer, National Harbor, MD (Abstract) Abstract : 2017.
Graul A, Latif N, Zhang X, Dean LT, Morgan M, Giuntoli R, Burger R, Kim S, Schmitz K, Ko E.: Incidence of venous thromboembolism by type of gynecologic malignancy and surgical modality in the National Surgical Quality Improvement Program International Journal of Gynecological Cancer 27(3): : 581-587,2017.